The Prosigna Gene Expression Assay and Responsiveness to Adjuvant Cyclophosphamide-Based Chemotherapy in Premenopausal High-Risk Patients With Breast Cancer

Breast Cancer Research - United Kingdom
doi 10.1186/s13058-018-1012-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Development and Verification of the PAM50-based Prosigna Breast Cancer Gene Signature Assay

BMC Medical Genomics
Genetics
2015English

Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

P53 Expression Status Is Associated With Cancer-Specific Survival in Stage III and High-Risk Stage II Colorectal Cancer Patients Treated With Oxaliplatin-Based Adjuvant Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2019English

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2018English

High-Dose Chemotherapy in High-Risk Breast Cancer

Breast Cancer Research
Cancer ResearchOncology
2000English

Population-Based Study of the Effect of Gene Expression Profiling on Adjuvant Chemotherapy Use in Breast Cancer Patients Under the Age of 65 Years

Cancer
Cancer ResearchOncology
2015English

The Use of a Cognitive Protectant to Help Maintain Quality of Life and Cognition in Premenopausal Women With Breast Cancer Undergoing Adjuvant Chemotherapy

2006English

High Expression of Class III Β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

Clinical Impact of Delaying Initiation of Adjuvant Chemotherapy in Patients With Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy